EP0634939A1 - Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central - Google Patents

Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central

Info

Publication number
EP0634939A1
EP0634939A1 EP94905206A EP94905206A EP0634939A1 EP 0634939 A1 EP0634939 A1 EP 0634939A1 EP 94905206 A EP94905206 A EP 94905206A EP 94905206 A EP94905206 A EP 94905206A EP 0634939 A1 EP0634939 A1 EP 0634939A1
Authority
EP
European Patent Office
Prior art keywords
neurotrophin
neurite growth
antibody
myelin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94905206A
Other languages
German (de)
English (en)
Inventor
Martin E. Schwab
Lisa Schnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Canton of Erziehungsdirektion
Original Assignee
Zurich Canton of Erziehungsdirektion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Canton of Erziehungsdirektion filed Critical Zurich Canton of Erziehungsdirektion
Publication of EP0634939A1 publication Critical patent/EP0634939A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
  • PNS peri ⁇ pheral nervous system
  • CNS central nervous system
  • Neurite growth from implanted embryonic CNS tissues in adult rat CNS has been found in some cases to reach up to 14 mm within some gray matter areas, but has not been found to exceed 1 mm within white matter (Nornes et al., 1983, Cell Tissue Res. 230:15-35; Bjorklund and Stenevi, 1979, Physiol. Rev. 59:62-95; Commission, 1984, Neuroscience 12:839-853). On the other hand, extensive regenerative growth has been found in the
  • the differentiated CNS may lack cellular or substrate constituents that are conducive for neurite growth during development (Liesi, 1985, EMBO J. 4:2505-2511; and Carbonetto et al, 1987, J. Neurosci. 7:610-620), or it may contain components which are nonpermissive or inhibitory for nerve fiber regeneration (Schwab and Thoenen, 1985, J. Neurosci. 5:2415-2423).
  • a growth (cell proliferation) inhibi- tory factor for mouse neuroblastoma cells was partially purified and characterized from the culture medium of fetal rat glioblasts as well as from C6 rat glioma cells (Sakazaki et al., 1983, Brain Res. 262:125-135).
  • the factor was estimated to have a molecular weight of about 75,000 by gel filtration with BioGel P-20 with an isoelectric point of 5.8.
  • the factor did not appear to alter the growth rate or morphology of glial cells (C6) or fibroblasts (3T3) .
  • no significant nerve growth inhibitory factor activity was detected towards neuroblastoma cells (Neuro La, NS-20Y and NIE-115) or cloned fibroblasts (3T3) .
  • CNS myelin-associated proteins have been identified that inhibit neurite outgrowth.
  • Two oligodendrocyte-and myelin-associated membrane proteins; NI-35 (35kD) and NI-250 (250kD) were identified by in vitro and biochemical studies (Schwab and Caroni, 1988, J. Neurosci. 8 :2381-2393; Caroni and Schwab, 1988, J. Cell. Biol. 106:1281-1288) .
  • Monoclonal antibody IN-1 which neutralizes the activity of these constituents in various systems, has been shown to lead to regeneration of corticospinal tract (CST) axons in young rats over distances of up to 5-11 mm distal to a spinal cord lesion within 2 weeks (Int. Application No. 89912786.4, filed November 2, 1989, by Schwab et al.; U. S. Serial No. 07/401,212 by Schwab et al., filed August 30, 1989; U. S. Serial No. 07/719,692 by Schwab et al., filed June 24, 1991).
  • CST corticospinal tract
  • the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein. It is based, at least in part, on the discovery that monoclonal antibody IN-1, directed against a myelin- associated neurite growth inhibitor, together with a member of the neurotrophin family, (e.g. neurotrophin- 3 (NT-3) , brain-derived neurotrophic factor (BDNF) , or nerve growth factor (NGF) ) , was able to promote regeneration of neurites over long distances in the partially transected spinal cord of adult rats. Such distances significantly exceeded the regeneration resulting from antibody without neurotrophin family member.
  • NT-3 neurotrophin- 3
  • BDNF brain-derived neurotrophic factor
  • NGF nerve growth factor
  • NT-3 together with antibody directed toward myelin- associated neurite growth inhibitor, may be used to promote regeneration in the CNS.
  • Such methods may be directed toward the treatment of neurologic disorders, including trauma as well as degenerative conditions.
  • FIGURE 1 Sprouting of lesioned corticospinal tract fibers. The sprouting index was calculated by subtracting the branching index of normal, unlesioned animals.
  • A Sprouting at the lesion site, 1mm rostral to lesion, and 4mm rostral to lesion, following injection of human recombinant NT-3 or cytochrome C (control) .
  • B Sprouting at the lesion site, 1mm rostral to lesion, and 4mm rostral to lesion, following local injection of Ringer's solution (control) , BDNF, NGF, or NT-3 in rats intracerebrally carrying hybridoma cells producing monoclonal antibody IN-1.
  • FIGURE 2 Millimeters of elongation of corticospinal tract fibers (mm from the lesion site) 14-17 days post-lesion in rats intracerebrally carrying hybridoma cells producing monoclonal antibody IN-1, following local injection of Ringer's (control), human recombinant BDNF, human recombinant NGF or human recombinant NT-3.
  • the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
  • the neurotrophin family member is NT-3 and the antibody directed toward a myelin-associated neurite growth inhibitory protein is IN-1 (which was raised to PAGE-purified 250,000d fraction from rat spinal cord myelin) , as produced by hybridoma cell line IN-1 and deposited with the European Collection of Animal Cell Cultures (ECACC) , PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom, and assigned accession number 88102801.
  • ECACC European Collection of Animal Cell Cultures
  • the present invention relates to CNS myelin associated neurite growth inhibitory proteins.
  • the CNS myelin associated inhibitory proteins of the invention may be isolated by first isolating myelin . . . and subsequent purification therefrom. Isolation procedures which may be employed are described more fully in the sections which follow. Alternatively, the CNS myelin associated inhibitory proteins may be obtained from a recombinant expression system (see Section 5.3., infra) .
  • CNS myelin associated inhibitory proteins can be isolated from the CNS myelin of higher vertebrates including, but not limited to, birds or mammals.
  • Myelin can be obtained from the optic nerve or from central nervous system tissue that Includes but is not limited to spinal cords or brain stems. The tissue may be homogenized using procedures described in the art (Colman et al., 1982, J. Cell Biol. 95:598-608) .
  • the myelin fraction can be isolated subsequently also using procedures described (Colman et al., 1982, supra) .
  • the CNS myelin associated inhibitory proteins can be solubilized in detergent (e.g., Nonidet P-40TM, sodium deoxycholate) .
  • detergent e.g., Nonidet P-40TM, sodium deoxycholate
  • the solubilized proteins can subsequently be purified by various procedures known in the art, including but not limited to chromatography (e.g., ion exchange, affinity, and sizing chromatography) , centrifugation, electrophoretic procedures, differential solubility, or by any other standard technique for the purifica ⁇ tion of proteins.
  • the NI-35 (35 Kd) and NI-250 (250 Kd) myelin-associated neurite growth inhibitory proteins may be utilized (Caroni and Schwab, 1988, J. Cell Biol. 106:1281-1288; Schwab and Caroni, 1988, J. Neurosci. 8 . :2381-2393; Caroni and Schwab, 1988, Neuron 1:85-96).
  • the CNS myelin associated inhibi ⁇ tory proteins may be isolated and purified using immunological procedures.
  • the proteins can first be solubilized using detergent (e.g., Nonidet P-40TM, sodium deoxycholate) .
  • the proteins may then be isolated by immunoprecipitation with antibodies to the 35 kilodalton and/or the 250 kilodalton proteins.
  • the CNS myelin associated inhibitory proteins may be isolated using immunoaffinity chromatography in which the proteins are applied to an antibody column in solubilized form.
  • the neurite growth regulatory factors of the present invention can be characterized by assays based on their physical, immunological, or functional properties.
  • the functional activity of a putative neurite growth inhibitory factor may be confirmed by testing the ability of the factor to inhibit sprouting or growth of neurites or spreading of 3T3 cells on a polylysine-coated tissue culture dish (Int. Application No. 899127864 filed November 2, 1989 by Schwab et al., U. S. Serial No. 07/401,212 by Schwab et al. filed August 30, 1989, and U. S. Serial No. 07/719,692 by Schwab et al. filed June 24, 1991).
  • the half life of the neurite growth regulatory factors in cultured cells can be studied, for example, by use of cycloheximide, an inhibitor of protein synthesis (Vasquez, 1974, FEBS Lett.
  • a physiological receptor for a neurite growth regulatory factor could be identified by assays which detect complex formation with a neurite growth regulatory factor, e.g.. by use of affinity chromatography with immobilized neurite growth regulatory factor, binding to a labeled neurite growth regulatory factor followed by cross-linking and immunoprecipitation, etc.
  • Electrophoretic techniques such as SDS-polyacryl- amide gel electrophoresis and two-dimensional electro- phoresis can be used to study protein structure. Other techniques which can be used include but are not limited to peptide mapping, isoelectric focusing, and chromatographic techniques.
  • the amino acid sequences of primary myelin associated inhibitors can be derived by deduction from the DNA sequence if such is available, or alternatively, by direct sequencing of the protein, e.g. , with an automated amino acid sequencer.
  • the protein sequences can be further characterized by a hydrophilicity analysis (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) .
  • a hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the protein (and the corresponding regions of the gene sequence, if available, which encode such regions) .
  • Any mammalian cell can potentially serve as the nucleic acid source for the molecular cloning of the genes encoding the CNS myelin associated inhibitory proteins, including but not limited to the 35 kD and/or 250 kD myelin associated proteins described in Caroni and Schwab (1988, Neuron 1:85-96).
  • the DNA may be obtained by standard procedures known in the art from cloned DNA (e.g.. a DNA "library”) , by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired mammalian cell.
  • cloned DNA e.g.. a DNA "library”
  • chemical synthesis e.g., chemical synthesis
  • cDNA cloning e.g. a DNA "library”
  • Clones derived from genomic DNA may contain regulatory and intron DNA regions, in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, a given neurite growth regulatory factor gene should be molecularly cloned into a suitable vector for propagation of the gene.
  • DNA fragments are generated, some of which will encode the desired neurite growth regulatory factor gene.
  • the DNA may be cleaved at specific sites using various restriction enzymes.
  • DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication.
  • the linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.
  • the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961-3965).
  • a portion of a neurite growth regulatory factor amino acid sequence can be used to deduce the DNA sequence, which DNA sequence can then be synthesized as an oligonucleotide for use as a hybridization probe.
  • nucleic acid fractions enriched in neurite growth regulatory factor may be used as a probe, as an initial selection procedure.
  • a neurite growth regulatory factor gene can also be identified by mRNA selection using nucleic acid hybridization followed by in vitro translation or translation in Xenopus oocytes. In an example of the latter procedure, oocytes are injected with total or size fractionated CNS mRNA populations, and the membrane-associated translation products are screened in a functional assay (3T3 cell spreading) .
  • DNA fragments can be used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified neurite growth regulatory factor DNA, or DNA that has been enriched for neurite growth regulatory factor sequences. Immunoprecipitation analysis or functional assays of the in vitro translation products of the isolated mRNAs identifies the mRNA and, therefore, the cDNA fragments that contain neurite growth regulatory factor sequences.
  • mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against a neurite growth regulatory factor protein.
  • a radiolabelled neurite growth regulatory factor cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe to identify the neurite growth regulatory factor DNA fragments from among other genomic DNA fragments.
  • isolating the neurite growth regulatory factor genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the neurite growth regulatory factor gene. Other methods are possible and within the scope of the invention.
  • the identified and isolated gene or cDNA can then be inserted into an appropriate cloning vector.
  • vector-host systems known in the art may be used. Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc.
  • the neurite growth regulatory factor gene may be identified and isolated after insertion into a suitable cloning vector, in a "shot gun" approach. Enrichment for a given neurite growth regulatory factor gene, for example, by size fractionation or subtraction of cDNA specific to low neurite growth regulatory factor producers, can be done before insertion into the cloning vector.
  • DNA may be inserted into an expression vector system, and the recombinant expression vector containing a neurite growth regulatory factor gene may then be detected by functional assays for the neurite growth regulatory factor protein.
  • the neurite growth regulatory factor gene is inserted into a cloning vector which can be used to transform, transfect, or infect appropriate host cells so that many copies of the gene sequences are gene ⁇ rated.
  • cleaved vector and neurite growth regula ⁇ tory factor gene may be modified by homopolymeric tailing.
  • Identification of the cloned neurite growth regulatory factor gene can be accomplished in a number of ways based on the properties of the DNA itself, or alternatively, on the physical, immunological, or functional properties of its encoded protein.
  • the DNA itself may be detected by plaque or colony nucleic acid hybridization to labeled probes (Benton, W. and Davis, R. , 1977, Science 196:180; Grunstein, M. and Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961).
  • the presence of a neurite growth regulatory factor gene may be detected by assays based on properties of its expressed product.
  • cDNA clones or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that inhibits in vitro neurite outgrowth.
  • a neurite growth regulatory factor protein may be identified by detecting binding of antibody directed toward the factor to putative neurite growth regulatory factor- synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.
  • transformation of host cells with recombinant DNA molecules that incorporate an isolated neurite growth regulatory factor gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene.
  • the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.
  • the recombinant DNA molecule that incorporates a neurite growth regulatory factor gene can be modified so that the gene is flanked by virus sequences that allow for genetic recombination in cells infected with the virus so that the gene can be inserted into the viral genome.
  • neurite growth regulatory factor DNA- containing clone After the neurite growth regulatory factor DNA- containing clone has been identified, grown, and harvested, its DNA insert may be characterized as described in Section 5.3.4, infra.
  • infra When the genetic structure of a neurite growth regulatory factor gene is known, it is possible to manipulate the structure for optimal use in the present invention.
  • promoter DNA may be ligated 5' of a neurite growth regulatory factor coding sequence, in addition to or replacement of the native promoter to provide for increased expression of the protein. Many manipulations are possible, and within the scope of the present invention. 5.3.2. EXPRESSION OF THE CLONED NEURITE GROWTH REGULATORY FACTOR GENES
  • the nucleotide sequence coding for a neurite 5 growth regulatory factor protein or a portion thereof can be inserted into an appropriate expression vector, i.e. , a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
  • an appropriate expression vector i.e. , a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
  • translation signals can also be supplied by the native neurite growth regulatory factor gene and/or its flanking regions.
  • a variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to
  • virus e.g. , vaccinia virus, adenovirus, etc.
  • insect cell systems infected with virus e.g. , baculovirus
  • microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA
  • plasmid DNA 2 0 plasmid DNA, or cosmid DNA.
  • the expression elements of these vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcrip ⁇ tion and translation elements may be used.
  • sequences may include in vitro recombinant DNA and synthetic techniques and in vivo recombinations (genetic recombination) .
  • Expression vectors containing neurite growth regulatory factor gene inserts can be identified by
  • 35 three general approaches (a) DNA-DNA hybridization, (b) presence or absence of "marker” gene functions, and (c) expression of inserted sequences.
  • the presence of a foreign gene inserted in an expression vector can be detected by DNA-DNA hybridization using probes comprising sequences that are homologous to an inserted neurite growth regulatory factor gene.
  • the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g. , thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector.
  • certain "marker” gene functions e.g. , thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
  • recombinants containing the neurite growth regulatory factor insert can be identified by the absence of the marker gene function.
  • recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based on the physical, immuno ⁇ logical, or functional properties of a given neurite growth regulatory factor gene product. Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombi ⁇ nant expression vectors can be propagated and prepared in quantity.
  • the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g. _ lambda) , and plasmid and cosmid DNA vectors, to name but a few.
  • a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered neurite growth regulatory factor protein may be controlled.
  • different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g.. glycosylation, cleavage) of proteins.
  • Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
  • expression in a bacterial system can be used to produce an unglycosylated core protein product.
  • Expression in yeast will produce a glycosylated product.
  • Expression in mammalian (e.g. COS) cells can be used to ensure "native" glycosylation of the heterologous neurite growth regulatory factor protein.
  • different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extends.
  • the gene product can be purified as described in Section 5.1, supra. and analyzed as described in Section 5.2, supra.
  • amino acid sequence of a given neurite growth regulatory factor protein can be deduced from the nucleotide sequence of the cloned gene, allowing the protein, or a fragment thereof, to be synthesized by standard chemical methods known in the art (e.g.. see Hunkapiller, et al., 1984, Nature 310:105-111).
  • such neurite growth regulatory factor proteins include but are not limited to those containing altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
  • one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
  • Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
  • the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine, and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
  • neurite growth regulatory factor proteins which are differentially modified during or after translation, e.g. _ by glycosylation, proteolytic cleavage, etc.
  • the structure of a given neurite growth regulatory factor gene can be analyzed by various methods known in the art.
  • the cloned DNA or CDNA corresponding to a given neurite growth regulatory factor gene can be analyzed by methods including but not limited to Southern hybridization (Southern, 1975, J. Mol. Biol. 98:503- 517), Northern hybridization (Alwine, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5350-5354; Wahl, et al., 1987, Meth. Enzymol. 152:572-581), restriction endonuclease mapping (Maniatis, et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) , and DNA sequence analysis.
  • DNA sequence analysis can be performed by any techniques known in the art including but not limited to the method of Maxa and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467), or use of an automated DNA sequenator (e.g.. Applied Biosystems, Foster City, CA) .
  • Antibodies can be produced which recognize neurite growth regulatory factors or related proteins. Such antibodies can be polyclonal or monoclonal.
  • a neurite growth regulatory factor protein or a synthetic protein, or fragment thereof, including but not limited to rabbits, mice, rats, etc.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not * limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebac- teriu parvum.
  • BCG Bacille Calmette-Guerin
  • corynebac- teriu parvum corynebac- teriu parvum
  • a monoclonal antibody to an epitope of a neurite growth regulatory factor can be prepared by using any technique which provides for the production of anti ⁇ body molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256:495-497), and the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) and EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • the monoclonal antibody is produced by cell line IN-1, deposited with ECACC and having accession number 88102801. In additional embodiments, the monoclonal antibody is produced by cell line IN-2, deposited with the ECACC and having accession number 88102802.
  • the monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies. Human mono ⁇ clonal antibodies may be made by any of numerous techniques known in the art (e.g.. Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A.
  • Chimeric antibody molecules may be prepared containing a mouse antigen- binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851, Takeda et al., 1985, Nature 314:452).
  • a molecular clone of an antibody to a neurite growth regulatory factor epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A
  • Antibody molecules may be purified by known techniques, e.g.. immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography) , or a combination thereof, etc.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • such fragment's include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, and the 2 Fab or Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
  • the present invention relates to methods of promoting central nervous system regeneration in a subject in need of such treatment comprising administering a therapeutically effective amount of an essentially purified and isolated neurotrophin family member together with an antibody directed toward a myelin-associated neurite growth inhibitory protein.
  • Neurotrophin family members include, but are not limited to, BDNF, as described in PCT Publication No. WO 91/03568 published March 21, 1991 (corresponding to United States Serial No. 07/570,657 by Barde et al.); NT-3, as described in PCT publication No. WO 91/03569 published March 21, 1991 (corresponding to United States Serial No. 07/570,189 by Barde et al.); NGF, as described in United States Patent No.
  • the species of origin of neurotrophin used is the same species as the subject being treated.
  • the neurotrophin may be essentially purified and isolated using methods set forth in the cited references or known in the art.
  • Antibodies that may be used according to the invention include, but are not limited to, IN-1. Methods of promoting central nervous system regeneration may be measured by quantitatively or qualitatively evaluating neurite sprouting or fiber extension or by evaluating recovery of neurological function, using clinical parameters or methods such as those set forth in Section 6, infra.
  • Subjects in need of such treatment include human as well as non-human subjects suffering from a disorder of the central nervous system including but not limited to a disorder caused by trauma, infarction, infection, embolism, malignancy, metabolic defect, exposure to a toxin, degenerative disorder, etc.
  • the subject is a human suffering from a neurological disorder that involves the corticospinal tract, including, but not limited to, spinal cord trauma, a yotrophic lateral sclerosis, primary lateral sclerosis, ischemia, stroke, multiple sclerosis, compression lesions, syringomyelia, and multiple systems degeneration.
  • the subject is a human suffering from a neurological disorder that involves the optic nerve.
  • treatment refers to the amelioration of symptoms associated with the neurological disorder or a prolongation of survival. In certain instances, a “cure” may be achieved, but the present invention is not so limited.
  • a therapeutically effective amount of neurotrophin and antibody refers to that amount that results in amelioration of symptoms or a prolongation of survival in a subject in need of such treatment.
  • the local concentration of neurotrophin may be between about 0.01 and 100 nanograms per gram tissue (net weight) and the local concentration of antibody directed toward myelin-associated neurite growth inhibitory protein may be between about 0.01 and 10 micrograms per gram tissue. Dosage may be determined using standard techniques, e.g. as described in Fingl and Woodbury, 1975, in "The Pharmacological Basis of Therapeutics," Fifth Edition, Goodman and Gil an, eds., Macmillin Publ., N. Y., pp. 1-46.
  • Neurotrophin and antibody may be administered by any suitable route, including, but not limited to, local application via surgery or injection, intravenous, intrathecal, subcutaneous, or intramuscular routes. Neurotrophin and antibody may also be administered via a cellular implant that secretes neurotrophin or antibody. Neurotrophin and antibody may be administered either together or separately by different routes. It is preferred, however, that concurrent exposure to both neurotrophin and antibody be achieved.
  • the present invention also provides for pharmaceutical compositions comprising neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein in a suitable pharmaceutical carrier.
  • NEUROTROPHIN 3 ENHANCES REGENERATIVE SPROUTING OF THE LESIONED CORTICOSPINAL TRACT
  • This antibody was raised against the PAGE-purified 250,000 protein fraction from rat spinal cord myelin, a preparation which was highly enriched in neurite growth inhibitory activity.
  • the antibodies secreted by the locally formed tumor reached the spinal cord via the cerebrospinal fluid. 14-17 days later, the corticospinal tract (CST) axons were traced by anterograde transport of wheat germ agglutinin-horseradish peroxidase (WGA-HRP) injected into the right sensory motor cortex. Rats were fixed and processed for HRP histochemistry one day later.
  • CST corticospinal tract
  • WGA-HRP wheat germ agglutinin-horseradish peroxidase
  • RESULTS Sprouting was quantified on complete serial, parasagital sections by counting all the labelled branches intersecting vertical lines at the lesion site 1 mm rostral and 4 mm rostral to the lesion. The numbers obtained were related to the number of labelled axons within the compact CST; the value for the normal collateral branching present in unlesioned animals was substracted in order to get a sprouting index.
  • Fig. la shows that spontaneous sprouting of lesioned adult CST fibers occurred at all three levels.
  • a single injection of NT-3 at the time of lesion greatly increased this sprouting. The effect was visible at the lesion site and at 1 mm, but was decreased at 4 mm, perhaps due to a penetration of the factor (Fig. la) .
  • Control injections with cytochrome C (Fig. la) or Ringer's solution alone (Fig. lb) were indistinguishable.
  • NT-3 neurotrophin 3
  • CST corticospinal tract
  • BDNF brain-derived neurotrophic factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés de stimulation de la régénération du système nerveux central chez un sujet necessitant un tel traitement, consistant à administrer une dose thérapeutiquement efficace d'un membre de la famille des neurotrophines purifié et isolé, avec un anticorps contre une protéine inhibitrice de la croissance des neurites associé à la myéline.
EP94905206A 1993-02-11 1994-02-08 Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central Withdrawn EP0634939A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1635493A 1993-02-11 1993-02-11
US16354 1993-02-11
PCT/IB1994/000011 WO1994017831A1 (fr) 1993-02-11 1994-02-08 Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central

Publications (1)

Publication Number Publication Date
EP0634939A1 true EP0634939A1 (fr) 1995-01-25

Family

ID=21776697

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94905206A Withdrawn EP0634939A1 (fr) 1993-02-11 1994-02-08 Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central

Country Status (7)

Country Link
EP (1) EP0634939A1 (fr)
JP (1) JPH07509002A (fr)
AU (1) AU5891394A (fr)
CA (1) CA2117889A1 (fr)
IL (1) IL108600A0 (fr)
WO (1) WO1994017831A1 (fr)
ZA (1) ZA94887B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576441B1 (en) 1995-12-06 2003-06-10 Sumitomo Pharmaceuticals Company, Limited Semaphorin Z and gene encoding the same
WO1998011216A1 (fr) 1996-09-11 1998-03-19 Sumitomo Pharmaceuticals Company, Limited Nouveau gene de semaphorine: semaphorine y
US6902730B1 (en) 1996-10-09 2005-06-07 Sumitomo Pharmaceuticals Company, Limited Semaphorin gene: Semaphorin W
CA2190418A1 (fr) * 1996-11-15 1998-05-15 Zhi-Cheng Xiao Systeme regulateur pour la croissance des neurones et des tumeurs neuronales; anticorps utilises a cette fin et applications
AU4964097A (en) 1996-11-15 1998-06-10 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin genes (i)
EP0878480A1 (fr) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Procédé pour ameliorer la régénération nerveuse
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
AU784349C (en) 2000-01-12 2006-09-28 Yale University Nogo receptor-mediated blockade of axonal growth
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
CA2549000A1 (fr) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Procede de traitement de troubles neurologiques
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100196540B1 (ko) * 1988-11-04 1999-06-15 마틴 이. 샤브 축색성장 조절인자
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
WO1993000427A2 (fr) * 1991-06-24 1993-01-07 Erziehungsdirektion Of The Canton Zurich Facteurs regulateurs de la croissance des neurites
JP2008027291A (ja) * 2006-07-24 2008-02-07 Hitachi Ltd ストレージ装置及びデータ保護方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9417831A1 *

Also Published As

Publication number Publication date
ZA94887B (en) 1994-08-23
JPH07509002A (ja) 1995-10-05
IL108600A0 (en) 1994-05-30
CA2117889A1 (fr) 1994-08-18
WO1994017831A1 (fr) 1994-08-18
AU5891394A (en) 1994-08-29

Similar Documents

Publication Publication Date Title
US6291247B1 (en) Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US10100100B2 (en) Metallothionein-derived peptide fragments
US8008259B2 (en) Neurotrophin-derived peptide sequences
US9044428B2 (en) Neuritogenic peptides
JP4638027B2 (ja) ヘパリン結合増殖因子（ｈｂｇｆ）ポリペプチド
JP2006087434A (ja) 新規な神経栄養因子
CA2129423A1 (fr) Recepteur de facteur de croissance hepatique
EP1124960A2 (fr) Facteur neurotrophique iii dependant de l'activite (adnf iii)
WO1998022499A9 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
WO1998022499A2 (fr) Systeme de regulation de la croissance tumorale neuronale et neurale, anticorps destines a cet effet et utilisations de ceux-ci
JPH07506488A (ja) ｎｅｕレセプターの組換え刺激因子
EP0634939A1 (fr) Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central
BRPI0614419A2 (pt) peptìdeos derivados de gdnf
WO1994017831A9 (fr) Association de la neurotrophine et d'un anticorps contre la proteine inhibitrice de la croissance de neurites associee a la myeline stimulant la regeneration du systeme nerveux central
CA2279231C (fr) Facteur neurotrophique iii dependant de l'activite (adnf iii)
JPH08500246A (ja) 細胞増殖の阻害剤，その調製および用途
US5504197A (en) DNA encoding neurotrophic growth factors
Sottile et al. Assembly of fibronectin molecules with mutations or deletions of the carboxyl-terminal type I modules
WO2007071248A2 (fr) Peptides derives de la famille des proteines s-100 favorisant la survie neuritogene et neuronale
EP2140000A1 (fr) Procede d'amelioration de la migration de cellules neurales precurseurs
WO1995026363A1 (fr) Neurotrophine-6: un nouveau membre de la famille des neurotrophines
CA2221391A1 (fr) Systeme de regulation du developpement des neurones et des tumeurs neurales, anticorps diriges contre lui et utilisations du systeme
MXPA00001234A (en) Heparin-binding growth factor (hbgf) polypeptides
JPH05506659A (ja) エピテリン類：新規なシステインに富む成長変調タンパク
WO2011135304A1 (fr) Ncam-vase et neurorégénération

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941110

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19950927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960410